HC Wainwright set a $10.00 price objective on Cardiome Pharma (NASDAQ:CRME) (TSE:COM) in a research report sent to investors on Wednesday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
Several other brokerages have also recently weighed in on CRME. Canaccord Genuity set a $5.00 target price on Cardiome Pharma and gave the company a buy rating in a research note on Wednesday, March 21st. Mackie raised Cardiome Pharma to a buy rating in a research note on Friday, December 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. Cardiome Pharma presently has a consensus rating of Hold and an average target price of $5.67.
Shares of CRME stock opened at $2.32 on Wednesday. Cardiome Pharma has a fifty-two week low of $1.29 and a fifty-two week high of $4.84. The stock has a market cap of $81.59, a P/E ratio of -2.58 and a beta of 0.22. The company has a quick ratio of 4.71, a current ratio of 5.52 and a debt-to-equity ratio of 1.67.
Cardiome Pharma Company Profile
Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome.
Receive News & Ratings for Cardiome Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma and related companies with MarketBeat.com's FREE daily email newsletter.